SCHEMBL30294191

SCHEMBL30294191

COc1cc2c(cnn2C(=O)OC(C)(C)C)nc1-c1cccc2c1CCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
UCHL1 P09936 1/20 0.35
ELANE P08246 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
TACR3 P29371 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
USP30 Q70CQ3 1/20 0.32
EGFR P00533 1/20 0.32
ITK Q08881 1/20 0.32
SHMT1 P34896 1/20 0.32
MAPT P10636 3/20 0.32
KDM4E B2RXH2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211124 1.00 EHMT2 (0.37) EHMT2NPC1RAB9AUCHL1ELANE
SCHEMBL29907184 0.95 EHMT2 (0.34) EHMT2NPC1RAB9AUCHL1ELANE
SCHEMBL23210848 0.88 NPC1 (0.41) NPC1RAB9AMEN1KMT2ATACR3
SCHEMBL30294194 0.86 ELANE (0.34) EHMT2NPC1RAB9AUCHL1ELANE
SCHEMBL23236616 0.86 ELANE (0.34) EHMT2NPC1RAB9AUCHL1ELANE
SCHEMBL29907194 0.82 PGK1 (0.32) NPC1RAB9AELANEMEN1KMT2A
SCHEMBL23210982 0.82 MEN1 (0.35) EHMT2NPC1RAB9AUCHL1MEN1
SCHEMBL29907071 0.82 MEN1 (0.35) EHMT2NPC1RAB9AUCHL1MEN1
SCHEMBL23211057 0.78 NPC1 (0.37) NPC1RAB9AMEN1KMT2ATACR3
SCHEMBL23211071 0.78 STAT3 (0.33) EHMT2UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 EHMT2 2296/4885NPC1 3370/4885RAB9A 3393/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 EHMT2 2296/4885NPC1 3370/4885RAB9A 3393/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 EHMT2 2296/4885NPC1 3370/4885RAB9A 3393/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 EHMT2 2296/4885NPC1 3370/4885RAB9A 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.